Sharon Larkin
Direktor/Vorstandsmitglied bei SENSEONICS HOLDINGS, INC.
Vermögen: 125 119 $ am 30.04.2024
Profil
Sharon D.
Larkin is currently the Director at Senseonics, Inc. and an Independent Director at Senseonics Holdings, Inc. Previously, she worked at Abbott Laboratories as the Divisional VP-HR & Medical Devices Group from 2011 to 2015.
She also served as the Senior VP-Human Resources & Administration at Assertio Therapeutics, Inc. from 2017 to 2020.
Ms. Larkin completed her undergraduate degree at Georgia Institute of Technology.
Bekannte Unternehmensbeteiligungen
Unternehmen | Datum | Anzahl der Aktien | Bewertung | Datum der Bewertung |
---|---|---|---|---|
01.04.2024 | 299 327 ( 0,06% ) | 125 119 $ | 30.04.2024 |
Aktive Positionen von Sharon Larkin
Unternehmen | Position | Beginn |
---|---|---|
SENSEONICS HOLDINGS, INC. | Direktor/Vorstandsmitglied | 08.12.2021 |
Senseonics, Inc.
Senseonics, Inc. Electronic ComponentsElectronic Technology Senseonics, Inc. develops transformative glucose monitoring products. It develops Senseonics continuous glucose monitoring system, an implantable continuous glucose monitoring system, which includes a miniaturized sensor and receiver that is inserted into the subcutaneous space under the skin to wirelessly transmit glucose levels to an external receiver. The company was founded by Michael James Barrett and Arthur E. Colvin in 1996 and is headquartered in Germantown, MD. | Direktor/Vorstandsmitglied | 01.12.2021 |
Ehemalige bekannte Positionen von Sharon Larkin
Unternehmen | Position | Ende |
---|---|---|
Assertio Therapeutics, Inc.
Assertio Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Assertio Therapeutics, Inc. engages in the manufacture and distribution of pharmaceutical products to treat pain and other central nervous system conditions. Its brands include Gralise, Zipsor, Lazanda, Cambia, NUCYNTA ER and NUCYNTA. The firm focuses on neurology, orphan and specialty medicines. The company was founded by John W. Shell on August 7, 1995 and is headquartered in Lake Forest, IL. | Verwaltungsdirektor | 01.01.2020 |
ABBOTT LABORATORIES | Personalreferent | 01.09.2015 |
Ausbildung von Sharon Larkin
Georgia Institute of Technology | Undergraduate Degree |
Erfahrungen
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Beziehungen
Beziehungen ersten Grades
Unternehmen ersten Grades
Herr
Frau
Aufsichtsräte
Führungskräfte
Unternehmensverbindungen
Börsennotierte Unternehmen | 2 |
---|---|
ABBOTT LABORATORIES | Health Technology |
SENSEONICS HOLDINGS, INC. | Electronic Technology |
Private Unternehmen | 2 |
---|---|
Assertio Therapeutics, Inc.
Assertio Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Assertio Therapeutics, Inc. engages in the manufacture and distribution of pharmaceutical products to treat pain and other central nervous system conditions. Its brands include Gralise, Zipsor, Lazanda, Cambia, NUCYNTA ER and NUCYNTA. The firm focuses on neurology, orphan and specialty medicines. The company was founded by John W. Shell on August 7, 1995 and is headquartered in Lake Forest, IL. | Health Technology |
Senseonics, Inc.
Senseonics, Inc. Electronic ComponentsElectronic Technology Senseonics, Inc. develops transformative glucose monitoring products. It develops Senseonics continuous glucose monitoring system, an implantable continuous glucose monitoring system, which includes a miniaturized sensor and receiver that is inserted into the subcutaneous space under the skin to wirelessly transmit glucose levels to an external receiver. The company was founded by Michael James Barrett and Arthur E. Colvin in 1996 and is headquartered in Germantown, MD. | Electronic Technology |